Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 15, 2023 07:00 ET | Source: Passage Bio

Passage Bio to Present Updated Interim Data from Imagine-1 Study for GM1 Gangliosidosis at 19th Annual WORLDSymposium™ 2023

– Updated interim data from first six patients in Phase 1/2 Imagine-1 study of PBGM01 for GM1 Gangliosidosis to be shared in oral platform and poster presentations PHILADELPHIA, Feb. 15, 2023 ...
January 20, 2023 16:01 ET | Source: Passage Bio

Passage Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Jan. 20, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
December 14, 2022 07:00 ET | Source: Passage Bio

Passage Bio Announces Positive Interim Clinical Data from First Six Patients with GM1 Gangliosidosis in Imagine-1 Study

Interim safety data up to 20 months showed the low and high dose of PBGM01 were well tolerated and had a favorable safety profileIntra-cisterna magna administration of PBGM01 resulted in...
November 10, 2022 07:00 ET | Source: Passage Bio

Passage Bio Reports Third Quarter 2022 Financial Results and Provides Business Updates

Dosed first patient in final cohort, Cohort 4, in dose-ascending phase of Imagine-1 clinical trial for GM1 gangliosidosis; expect to dose the final patient in this phase of the trial by year-endPlan...
November 08, 2022 07:00 ET | Source: Passage Bio

Passage Bio to Present at Guggenheim 4th Annual Immunology & Neurology Day

PHILADELPHIA, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
November 03, 2022 07:30 ET | Source: Passage Bio

Passage Bio to Report Third Quarter 2022 Financial Results on November 10, 2022

PHILADELPHIA, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
October 14, 2022 16:01 ET | Source: Passage Bio

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PHILADELPHIA, Oct. 14, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
October 10, 2022 07:00 ET | Source: Passage Bio

Passage Bio Announces Appointment of William Chou, M.D. as Chief Executive Officer

PHILADELPHIA, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...
September 26, 2022 07:00 ET | Source: Passage Bio

Passage Bio to Present at Chardan’s 6th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous...
August 19, 2022 16:01 ET | Source: Passage Bio

Passage Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

PHILADELPHIA, Aug. 19, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system...